MAP3K15

Across TCGA pan-cancer cohorts, MAP3K15 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated MAP3K15 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MAP3K15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAP3K15 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, ACC, and PRAD are the cancer types where MAP3K15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.069	0.688	<.001	18	view →
ACC	DFS	Median	All	0.066	0.667	.002	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
READ	OS	Median	II,III,IV	0.187	0.653	.030	6	view →
BRCA	OS	Median	II,III,IV	0.197	0.566	.010	6	view →
LUSC	OS	Median	All	0.343	0.829	<.001	6	view →
UCEC	OS	Median	II,III,IV	0.856	0.457	.046	2	view →
SCLC	OS	Median	All	0.405	0.783	.035	1	view →
LIHC	OS	Median	All	0.460	0.787	.023	1	view →
SKCM	DFS	Median	All	0.099	0.211	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

MAP3K15–BLCA (OS)

Open the BLCA breakdown →